Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM - finally out. Important data for the post platinum post IO disease space. Happy to be part of this endeavor on the IDMC. nejm.org/doi/full/10.10…

Great presentation of NEMIO trial with ddMVAC + durva +/- treme for MIBC with pCR 48% & 18% Tx discontinued, excellent effort GETUG ESMO - Eur. Oncology #ESMO23 OncoAlert we are completing accrual in a trial with aMVAC/pembro Fred Hutch Cancer Center in histology subtypes Ali Khaki Sarah P. Psutka MD MS

👀 TAR-210 the Phase 1 study Intravesical Erdafitinib in HR and IR NMIBC In patient w/ FGFR alteration 🟢IR-NMIBC 87% CR in a CHEMOABLATION setting!! 🔵HR-NMIBC 82% CR ➡️intravesical treatment has a great futur!! No more TURBT soon 🥺?

Presented today at #ESMO23: In patients with urothelial carcinoma, the addition of nivolumab to platinum-based chemotherapy resulted in longer median overall survival than platinum-based chemotherapy alone (21.7 months vs. 18.9 months). Full CheckMate 901 trial results:

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Agree with Sumanta K. Pal, MD, FASCO that Andrea Apolo, M.D. did an exceptional job (as always)! ESMO - Eur. Oncology #ESMO23 OncoAlert NCI CCR GU Malignancies

Glad to see that our paper including the latest evidence in Muscle-invasive Bladder Cancer is already available at European Urology Congratulations to all panel members and a special thanks to Prof Witjes for his leadership. sciencedirect.com/science/articl…

Andrea Necchi highlighted the potential of neoadjuvant therapy for #MIBC at #ESMO23. Neoadjuvant trials can accelerate drug approvals, improve survival, and provide bladder-sparing opportunities. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/45DRXh3 ESMO - Eur. Oncology

Our NEW Primer on Bladder cancer is live today! By Lars Dyrskjøt, Hansel, Efstathiou, Knowles, @MattGalsky, Jeremy Teoh & Dan Theodorescu. Check it out here: go.nature.com/3FxR0MF

Praxisverändernde Daten beim #Urothelkarzinom auf dem #ESMO23 - was verändert sich ab sofort in der Therapie? Was gab es sonst an neuen Erkenntnissen? Die #onkowissenTV GU Experten haben den Überblick - gleich reinklicken: onkowissen.tv/esmo-2023/?cha… philipp ivanyi Axel S. Merseburger

#ESMO2023- #bladdercancer #urothelialcarcinoma highlights: EV302, CHECKMATE901, THOR, DAD- Bradley McGregor & I discuss practical implications of the data in advanced disease GU Oncology Now Uromigos Bladder Cancer Advocacy Network -1) EV+pembro has a practice-changing impact in both

Online now: Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive #BladderCancer by Vignesh Packiam, MD and colleagues bjui-journals.onlinelibrary.wiley.com/doi/full/10.11…

Comparing BCG-relapsing and refractory nonmuscle invasive #BladderCancer. #ExpertCommentary Dr. Bishoy M. Faltas WCM Englander Institute for Precision Medicine discusses work by Tan et al. in BJU International > bit.ly/45taY6x Wei Shen Tan Valentina Grajales MD, MS Ashish M. Kamat, MD, MBBS Roger Li Neema Navai Kelly Bree

The European Association of Urology (EAU) EAU Guidelines in #BladderCancer are probably the most followed guidelines globally in #OncSurgery We are thankful for the invitation to present our 'challenges' to these guidelines - mainly our suggestions for improving what are already excellent guidelines by the

European Association of Urology (EAU) Petros Grivas Patrick Hensley, MD Prof Ananya💙 @achoud72.bsky.social Niyati Lobo Roberto Contieri Wei Shen Tan The guidelines suggest that extended template lymphadenectomy (LND) may be beneficial on the basis of low-quality evidence. Omitted from the discussion were results from the SWOG S1011 trial which along with data from the LEA trial, clearly affirm with level 1 evidence that a

JUST IN (and finally...): Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!! The time has finally come... via Business Wire Dana-Farber Lank Center for Genitourinary Oncology Tom Powles OncoAlert Oncology Brothers OncLive.com Targeted Oncology UroToday.com Uromigos Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network

Great news 💪 KN-564 adjuvant study in Kidney Cancer has shown OS benefit for adjuvant Pembrolizumab high5md Tom Powles OncoAlert OncLive.com UroToday.com Uromigos Yüksel Ürün Viktor Grünwald Marc-Oliver Grimm European Association of Urology (EAU) businesswire.com/news/home/2023…®

Treatment effectiveness in UT tumors/#BladderCancer with #neuoendocrine/small cell component ➡️Neoadjuvant⬆️ vs RC+/-adjuvant treatment ➡️Neoadjuvant IA/EP⬆️ vs MVAC/GC for down staging, path response, OS (145.4 vs 42.5 mo)👉euoncology.europeanurology.com/article/S2588-… 👉very good thread Omar Alhalabi, MD

Platinum-based chemotherapy is the standard of care for previously untreated unresectable or metastatic urothelial carcinoma, w/ cisplatin-based chemotherapy preferred for eligible pts. Full CheckMate 901 trial Research Summary by Michiel van der Heijden et al.: nej.md/3FmKbO6

Check out our paper BJU International: -> no oncologic benefit to extended PLND at RC in cN+ BCa regardless of periop chemo ~ 30% distant Mx ~ 13% locoregional rec ⛔️ cN+ is associated with a significant staging bias Thanks to Benjamin Pradere and Shahrokh F. Shariat doi.org/10.1111/bju.16…